share_log

Protalix Biotherapeutics Is Eligible To Receive A $20M Milestone Payment From Its Commercial Partner, Chiesi Global Rare Diseases, A Business Unit Of The Chiesi Group, Triggered By Fda Approval Of Elfabrio (Pegunigalsidase Alfa-Iwxj) For Fabry Disease

Protalix Biotherapeutics Is Eligible To Receive A $20M Milestone Payment From Its Commercial Partner, Chiesi Global Rare Diseases, A Business Unit Of The Chiesi Group, Triggered By Fda Approval Of Elfabrio (Pegunigalsidase Alfa-Iwxj) For Fabry Disease

Protalix Biotherapeutics有資格從其商業合作伙伴Chiesi集團旗下的業務部門Chiesi Global Rare Disease獲得2000萬美元的里程碑式付款，這是由美國食品藥品管理局批准Elfabrio（Pegunigalsidase Alfa-iwxj）治療法布里病而觸發的
Benzinga ·  2023/05/18 18:52

Protalix Biotherapeutics Is Eligible To Receive A $20M Milestone Payment From Its Commercial Partner, Chiesi Global Rare Diseases, A Business Unit Of The Chiesi Group, Triggered By Fda Approval Of Elfabrio (Pegunigalsidase Alfa-Iwxj) For Fabry Disease

Protalix Biotherapeutics有資格從其商業合作伙伴Chiesi集團旗下的業務部門Chiesi Global Rare Disease獲得2000萬美元的里程碑式付款，這是由美國食品藥品管理局批准Elfabrio（Pegunigalsidase Alfa-iwxj）治療法布里病而觸發的

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論